Expanded Access Program (EAP) for Avapritinib
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Avapritinib (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions; Expanded access
- Sponsors Blueprint Medicines
Most Recent Events
- 24 Oct 2024 Status changed from recruiting to completed.
- 16 Nov 2022 Status changed from completed to recruiting.
- 05 Oct 2021 Status changed from recruiting to completed.